Neuroplast
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Urmonderbaan 22, Geleen, Limburg, 6167, ...Phone Number
+31 850761000Website
www.neuroplast.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neuroplast
Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions. The company was founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. Current investors are Lumana Invest, Brightlands Venture Partners, LIOF and the Netherlands Enterprise Agency. Neuroplast is located in Brightlands Chemelot Campus in The Netherlands.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuroplast your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Neuroplast has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Neuroplast
Check out if Neuroplast is spiking on competitors!
Click to see if Neuroplast had a recent Job posting/layoffs
Earning: See what the market has to say on Neuroplast recently announced quarterly report
Funding: Get notified immidiatlly once Neuroplast has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neuroplast launches new products
Neuroplast, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Neuroplast
Find more new buyers
Company Profile Activity
Activity Insights
Neuroplast is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neuroplast is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neuroplast.
Neuroplast financials insights
Gather financial insights about Neuroplast, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$11.5M
Neuroplast Tech Stack
A closer look at the technologies used by Neuroplast
Neuroplast News & Media
Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases
Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product designation or orphan disease designation (ODD) grants the holder a fast-track development pathway to market authorization with market...Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury
Neuro-Cells® treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following trauma The randomized, placebo-controlled, international multi-center Phase II clinical trial will determine efficacy for treatment of Traumatic Spinal Cord Injury...Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury
GELEEN, Netherlands, Nov. 17, 2021 /PRNewswire/ -- Dutch clinical phase biotech Neuroplast raised a total of € 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands Venture Partners, LIOF, and from the Innovation Credit from the Netherlands Enterprise Agency,...Dutch stem cell biotech Neuroplast announces successful clinical Phase I trial with Neuro-Cells® stem cell treatment for Traumatic Spinal Cord Injury
GELEEN, Netherlands, Nov. 9, 2021 /PRNewswire/ -- Dutch clinical phase biotech company Neuroplast and Hospital Nacional de Parapléjicos de Toledo in Spain, today announced positive clinical Phase I results after analysis of ten patients suffering from Traumatic Spinal Cord Injury (TSCI)....
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Neuroplast
Sign Up For FreeTo access detailed company insights
Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions. The company was founded in August 2014 by physician Johannes de Munte... Read More
